FDA alignment supports traditional approval path for Genelux Corporation, coinciding with Groen's appointment to executive leadership.
1 report, 1 independent
Updated Aug 8
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA alignment supports traditional approval path for Genelux Corporation, coinciding with Groen's appointment to executive leadership.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Genelux Corporation
biopharmaceutical company
Nothing else this week.
Related events
- Michael Davis takes a permanent leadership role at the FDA's Center for Drug Evaluation and Research following senior selections announced by the Department of Health & Human Services.
- FDA approval enables commercial opportunity involving CBRE Group.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- FDA guidance changes affect biosimilar approval, impacting Coherus Oncology, Inc.
Coverage
Newest first; wire copies grouped- GlobeNewswireGenelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates WESTLAKE VILLAGE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX),